Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits
Pooled result · MACEResult — go to the resultHazard ratio 0.92 95% CI 0.83–1.02Authors' conclusion
Tirzepatide provides clinically significant, multiorgan benefits across heart failure, MASH, sleep apnea, blood pressure, lipids, and inflammation.
Study context
- Population
- RCTs of tirzepatide (≥24 weeks) reporting cardiovascular, HF, renal, MASH, obstructive sleep apnea, blood pressure, lipid, quality of life, body composition or inflammatory outcomes; searched to January 2026
- Participants
- 25,847 participants17 RCTs
- Comparison
- Tirzepatide vs comparators across 10 health domains beyond T2D and obesity
- Outcome
- MACE
Methodological detailsrandom-effects models, Cochrane Risk of Bias 2, GRADE certainty rating
- Random-effects models
- Cochrane Risk of Bias 2
- GRADE certainty rating
Pooled result
As reported in the abstract
Hazard ratio
0.92
95% CI 0.83–1.02
Tirzepatidevs Dulaglutide
HR 0.92 (95% CI 0.83–1.02)
Further pooled results
CV death or HF events in HF with preserved ejection fraction
- Reduction in CV death or HF events
- 38%
- HR
- 0.62 (95% CI 0.41-0.95)
MASH resolution
- MASH resolution, % of patients
- 62%
- RR
- 5.33
Apnea-hypopnea index
- Clinically significant apnea-hypopnea index reduction
- 21.9 events/hour
Systolic blood pressure
- Systolic blood pressure reduction
- 5.8 mmHg
TG
- TG reduction
- 19.6%
eGFR
- eGFR preservation
- +1.5 mL/min/year
High-sensitivity C-reactive protein
- High-sensitivity C-reactive protein reduction
- 32.9%
Original publication
Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits. Endocr Pract. Published 28 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →